Sparian Biosciences Awarded $19.5 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-226 for Opiate Use Disorder/ Opiate Withdrawal Syndrome Through Phase 1 Clinical Development Sparian Biosciences announced that it has been awarded a $19.5 million, five-year grant to fund development of SBS-226

Sparian Biosciences Announces Formation of its Science Advisory Board ​NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Sparian Biosciences, Inc. (“Sparian”), a clinical-stage CNS-focused biopharmaceutical company, is proud to announce formation of a Science Advisory Board...

Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000 Sparian Biosciences announced results from the Phase 1 clinical trial of the first in class novel AEAr agonist analgesic SBS-1000.

Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment of stimulant use disorder (e.g., cocaine and methamphetamine)Grant awarded by...